Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients

NCT00386529 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2010-12-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the influence of aspirin on blood pressure in well-controlled hypertensive patients who receive low dose aspirin at different times of the day

Conditions

  • Well-controlled Hypertension

Interventions

DRUG

Aspirin enteric coated pellests 100mg

Sponsors & Collaborators

  • Kyungpook National University Hospital

    collaborator OTHER
  • The Catholic University of Korea

    collaborator OTHER
  • Cheil General Hospital and Women's Healthcare Center

    collaborator OTHER
  • Inje University

    collaborator OTHER
  • Keimyung University

    collaborator OTHER
  • Seoul National University Bundang Hospital

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • Yeungnam University Hospital

    collaborator OTHER
  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Shung Chull Chae, Professor · Kyungpook National University Hospital

  • Dong Ju Choi, Professor · Seoul National University Bundang Hospital

  • Dong Su Kim, Professor · Inje University

  • Jeong Bae Park, Professor · Cheil General Hospital and Women's Healthcare Center

  • Nam Sik Chung, Professor · Severance Hospital

  • Sang Hong Baek, Professor · The Catholic University of Korea

  • Chang Wook Nam, Professor · Keimyung University Dongsan Medical Center

  • Young Jo Kim, Professor · Yeungnam University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-01-31
Completion
2008-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00386529 on ClinicalTrials.gov